Abstract: Retinoic acid (RA) induced the terminal differentiation of a human embryonal carcinoma cell line (NT2/ Dl) into several morphologically distinct cell types, including the postmitotic CNS neurons.
Retinoic acid (RA), a derivative of vitamin A, induces differentiation in many cell types such as epithehal and cancer cells (De Luca, 1991) . In addition to its use as therapeutic agents for the treatment of acute promyelocytic leukemia ( Warrell et al., 1991) , RA has been suggested to be important in CNS development when the receptors for RA and retinoids were identified in the developing nervous system (Maden et al., 1990; Dencker et al., 1991) . The effects of RA are mediated by the interaction of its higand-receptor complexes with specific DNA response elements, including the RA response elements (RARES) or retinoid X response elements (RXRES) (Leid et al., 1992) . Increasing evidence has been accumulated on the role of RA in embryogenesis, such as pattern formation (Conlon, 1995; Kraft et al., 1994) , but little is known on the molecular mechanism by which RA induces neuronal differentiation.
Following treatment with RA for more than 3 weeks, a human embryonal carcinoma cell line, NTera2 cl.D1 (NT2/D1), was demonstrated to differentiate into several morphologically distinct cell types, including terminally differentiated postmitotic CNS neurons (Andrews, 1984; Andrews et al., 1984; Pleasure and Lee, 1993) . NT2/D1 cells represent the most extensively studied human embryonal carcinoma cells that are capable of differentiating into neurons (Andrews, 1988; Pleasure et al., 1992) ; these cells serve as a good model system for the study of the molecular mechanism by which RA induces neuronal differentiation in the human CNS. For example, RA was demonstrated to down-regulate the expression of growth factors, including transforming growth factor-ct and basic fibroblast growth factor, and protooncogenes, such as cmyc and N-myc, while up-regulating two homeotic genes, Hox 2.1 and Hox 2.2 (Miller et al., 1990) . These responses to RA were mediated through the RA nuclear receptor-)' (Moasser et al., 1994) . Furthermore, a recent study from our laboratory has suggested that RA-induced CNS neuronal differentiation may be mediated through the coordinated regulation of the neurotrophin receptors (Cheung et al., 1996) .
To identify stage-specific proteins, various differential cDNA screening methods have been developed. Major approaches include differential hybridization (Dworkin and David, 1980) , subtractive hybridization (Travis and Sutcliffe, 1988; Watson et al., 1990) , PCR-based cell-specific cDNA library construction (Belyavsky et al., 1989; Welsh et al., 1990) , RNA fingerprinting by arbitrarily primed PCR (RAP-PCR) (Welsh et al., 1992) , and differential display (Liang and Pardee, 1992) . Both RAP-PCR and differential display allow for an estimation of the expression of certain transcripts in response to a specific experimental treatment or developmental cues. In the present study, we have used RAP-PCR (Welsh et al., 1992) to evaluate the pattern of gene expression and to identify the candidate genes that are regulated during the process of RA-induced neuronal differentiation. RAP-PCR provides a basis for the selection of genes that are involved in the RA-induced differentiation in the human CNS. RNA fingerprints resulting from different patterns of transcript expression in response to RA treatment of NT2/D 1 cells were compared. Differentially amplified products were cloned and sequenced, and their expression during the course of RA treatment in NT2/D 1 cells was examined by northern blot analysis.
MATERIALS AND METHODS

Cell culture
NT2/Dl cells were cultured as previously described (Pleasure et al., 1992) . In brief, cells were seeded at 2 X 106 cells per 75-cm 2 flask in Dulbecco's modified Eagle's medium (DMEM; high glucose formulation; GIBCO) supplemented with 10% fetal bovine serum (FBS; GIBCO) and were subsequently maintained in OptiMEMI reduced-serum medium (GIBCO) supplemented with 5% FBS. Cells were differentiated with 10 1iM all-trans RA (Sigma) in DMEM supplemented with 10% FBS. Fresh medium was replenished every 3 days for various intervals (0-14 days).
RNA preparation and northern analysis
Total RNA was prepared using TRIZOL reagent (GIBCO). Ten micrograms of total RNA prepared from cells treated with RA for various intervals was electrophoresed through a formaldehyde agarose gel and transferred onto a nylon filter (MSI). Adult rat brain or liver RNAs were included as controls in each gel. Equal loading of RNA samples was indicated by the similar intensity of the ribosomal RNA bands on the ethidium bromide-stained gel. Hybridization was performed using a random-32P-labeled purified eDNA probe at 60°Cin phosphate buffer. Membranes were exposed to Kodak X-Omat film at -70°Cfor 1-7 days using Lightning Plus intensifying screens.
Arbitrary primers
Primers used in RAP-PCR included HNest5 primer 
RAP-PCR
RAP-PCR was performed as described (Welsh et al., 1992) . In brief, 10 pl of each RNase-free DNaseI (Promega)-treated total RNA (5 and 15 ng/ptl) was combined with 10~il of 2x RT mix, which contained 2X Superscript first-strand buffer, 20 mM dithiothreitol, 200 jiM each deoxynucleotide triphosphate, 20 U of RNasin (Promega), 2 jiM primer, and 200 U of Superscript II RNaseH -reverse transcriptase. RT was performed at 37°Cfor 1 h. Twenty microliters of AP-PCR master mix, which contains 2x Taq polymerase buffer, 4 mM MgC1 2, 200 jiM each deoxynucleotide triphosphate, 1 jiM primer, 0.1 U of Taq polymerase (GIBCO), and 0.4 jil of [y-32P]dCTP. AP-PCR was composed of a low-stringency cycle followed by 30 high-stringency cycles. During the low-stringency cycle, the reaction mix was allowed to go through a denaturing step at 94°C for 5 mm, annealed at 35°C for 5 mm, and then extended for 5 mm at 72°C.High-stringency cycles include denaturation at 94°Cfor 1 mm, annealing at 55°Cfor 1.5 mm, and extension for 1.5 mm at 72°C.Four microliters of amplified products was mixed with 18 jil of 95% formamide and heated at 94°Cfor 2 mm, and 2.5 j.d of this heated mixture was electrophoresed in denaturing 6% polyacrylamide gel. Differentially expressed PCR product bands were excised from the gel and reamplified with the primers for RT and AP-PCR for 30 cycles in the absence of radioactive isotopes. Reamphified cDNA was gel-purified with Qiaex (Qiagen) and cloned.
Cloning and sequencing analysis
Purified cDNA fragments were cloned using the pCRScript SK+ cloning kit (Stratagene) as described by the vendor. Plasmid DNAs were prepared by the alkaline lysis method, and double-stranded DNA sequencing was performed with the T3/T7 primer set using the T7 DNA polymerase sequencing kit (Pharmacia). The average length of the clones obtained was -~450bp. The rate of false positives, including the possibilities of isolation of rRNA genes, was
RESULTS
RAP-PCR
To identify transcriptionally regulated genes that are potentially involved in the RA-induced neuronal differentiation process, RAP-PCR was performed using total RNA derived from NT2/D1 cells treated with or without RA for various intervals. In the isolation of early-response genes, RNA fingerprinting patterns for no RA treatment versus treatment for 1, 2, and 3 days were compared, whereas patterns obtained for RA treatment of 3 or 7 days were used to identify lateresponse genes. To compensate for the possible occurrence of differentially amplified products that reflect the concentration or quality difference among the RNA samples , each RNA sample was fingerprinted in at least two threefold dilutions. Only differentially amplified products reproducibly present in both dilutions were considered as positively selected bands. RAP-PCR amplifications with five dif- The RT primer and the AP-PCR primer were used for the first-strand synthesis and AP-PCR in RAP-PCR, respectively. The expression pattern was obtained by northern analysis using total RNA prepared from NT2IDI cells treated with RA for various intervals. Gene identity indicates the gene producing the highest scoring segment pair when the cloned amplified RAP-PCR product was aligned to the deduced amino acid sequences using databases listed in the text. Homology indicates the percentage of homology between the deduced amino acid sequence of the cloned amplified RAP-PCR product and the gene identity listed.
ferent combinations of the primers (as described in Materials and Methods) revealed 11 differentially expressed patterns. Two constitutively expressed bands were selected to serve as controls in subsequent analysis.
Sequence analysis of the cloned differentially expressed PCR fragments
Differentially amplified products were reamplified with the arbitrary primers that were used for RT and AP-PCR. The reamplified products were cloned into pCRScript SK+ vector and were then sequenced using T3 and T7 primers. In most cases, more than three individual clones were being sequenced for each amplified product. The nucleotide sequences were compared with the GenBank, EMBL, DDBJ, and PDB databases. Deduced amino acid sequences were compared with the CDS translations of the GenBank database and the amino acid sequences from the PDB, SwissProt, Spupdate, and PIR databases. In both cases, the BLAST server provided by the National Center for Biotechnology Information (National Library of Medicine, National Institutes of Health) was used for performing the sequence analysis. TBLASTX was also attempted with the dbEST database at the National Center for Biotechnology Information. Clones obtained by RAP-PCR can be classified into three groups: constitutively expressed or up-regulated or down-regulated during the course of RA treatment (Table 1) . Among the 13 amplified bands, five novel genes were obtained. Three of these novel clones were up-regulated, whereas one was down-regulated during RA treatment. Furthermore, one of the two constitutively expressed control bands isolated was found to be novel. Clones 1. 31, 7.31, 8.31, 12.33, 15.31, and 19 .41 were isolated using HNest5 primer as an arbitrary primer for RT and HTrkB5A primer as an arbitrary primer for AP-PCR. Using HVim5 as the arbitrary primer for RT, Ml3seq primer yielded clones 28.19, 29.2, and 32.2, whereas Ml3rev primer gave clone 30.2 when used for AP-PCR. Similarly, the combination of Ml 3seq as RT primer and Ml 3rev as AP-PCR primer yielded clones 37.6, 41.9, and 44.4 (Table 1) .
RNA blot analysis of RA-induced differentially expressed cDNA fragments
The cloned amplified products were analyzed by northern blot analysis to examine their pattern of expression in NT2/D1 cells during the course of RA treatment (3-14 days).
Seven clones, including 12. 33, 28.19, 30.2, 32.2, 1.31, 29.2, and 44.4 , were found to be up-regulated during RA treatment of NT2/D1 cells. Clone 12.33, which shares 100% homology with the nucleotide sequence of human CD59, an LY-6-like protein expressed in human lymphoid cells (Davies et al., 1989) , and clone 30.2, which shares 100% nucleotide sequence homology with the 3' end of the core protein of human heparan sulfate proteoglycan (HSPG), were transcriptionally induced after 7 and 14 days of RA treatment ( Fig. 1A and C) . A prominent transcript ('-~6 kb) for clone 28.19 was detected following 3 days of RA treatment; this clone was found to be 100% homologous to the human transcription factor SUPT4H mRNA (Fig. 1B) . Clone 32.2 shares 95% homology with mRNA encoding the human cadherin-6 gene; three RA-induced transcripts were detected at day 7, and the expression was reduced at day 14 (Fig. 1D) . The expression of three novel clones, 1.31, 29.2, and 44.4, was up-regulated during the course of RA treatment. Basal level of expression for all three novel genes could be detected when the NT2/D 1 cells were cultured in the absence of RA. Although basal expression of the transcript for clone 1.31 was low, it was induced and peaked at day 7. Clone 1.31 did not crosshybridize with the rat brain and liver control ( Fig. 2A) , which might be due to the low sequence homology of this gene with that of its rat counterparts. Alternatively, it is also possible that the partially cloned novel gene was not expressed in both the adult brain and liver. The expression of clone 44.4 remained constant at day 0 and day 3 but was induced at day 7 and remained constant at day 14. Similar to clone 1.31, no crosshybridization was detected in rat brain or rat liver for clone 44.4 (Fig. 2B) . The expression of the novel clone 29.2 was induced steadily along the course of RA treatment. It is interesting that the transcript for clone 29.2 was detected in rat brain but not liver (Fig. 2C) .
RNA blot analysis of iLk-down-regulated differentially expressed cDNA fragments
Among the differentially amplified clones, clones revealed a '-'5-kb transcript that was down-regulated from day 0 to day 7 following RA treatment. However, similar to clones 1.31 and 44.4, no signal for clone 8.31 was detected in rat brain or liver (Fig. 2D) . The RA-induced down-regulation was also observed for clone 15.31 (Fig. 3A) ; this clone shares 82% homology with the amino acid sequence of human dystroglycan. Similarly, another differentially amplified gene (clone 41.9), showing 92% homology with the mouse monocarboxylate transporter gene, was slightly downregulated along the course of RA treatment (Fig. 3B ).
The expression of clone 37.6, which is 100% homologous to the deduced amino acid sequence of the DEAD-box protein, was decreased at 7 days after RA treatment (Fig. 3C ).
Clathrin gene (clone 7.31), isolated as a band constitutively amplified during RA treatment, was constitutively expressed along the course of RA treatment studied (Fig. 4A) . It is interesting that another clone, 19.41, that showed constitutive expression from day 0 to day 14 revealed no homology with any known sequences. The expression of its transcript was found to be at least three times higher in rat brain than in rat liver (Fig. 4B) .
DISCUSSION
Our studies were aimed at the identification of genes that are differentially regulated in responseto RA treatment. This provides clues for the studies of the genes that are involved in RA-induced neuronal differentiation in the human CNS. With the use of five pairs of arbitrarily chosen primers, which have been designed for use in other studies, 11 differentially expressed bands were isolated. Among these differentially amplified PCR fragments, seven of them were demonstrated to be up-regulated, whereas four of them were downregulated during RA treatment. Two constitutively expressed bands were isolated as controls for the present study. Among the 13 clones thus far isolated and examined, five of them were novel clones, sharing no homology with any nucleic acid or amino acid sequences available in the databases listed.
Human transcription factor SUPT4H was found to share 42% homology with the Spt4p gene of Saccharomyces cerevisiae.~pt~p is crucial for normal chromatin structure and transcription in S. cerevisiae, but SUPT4H has only been recently demonstrated to encode a nuclear protein that is expressed in all human tissues examined (Hartzog et al., 1996) . Little has been discussed on the role of this transcription factor in the neuronal differentiation process. Another gene of interest is the HSPG gene, encoded by clone 30.2. Different HSPGs have been demonstrated to be important in embryogenesis and brain development (Gould et al., 1995; Watanabe et al., 1995) . HSPGs have also been suggested to play important roles in regulating the responses of neuronal precursor cells to particular growth factors (Ford et al., 1994) . The level of a specific HSPG, perlecan, was previously demonstrated to be markedly increased during neuronal differentiation in a murine embryonal carcinoma cell line, P19. This increase was demonstrated to be concomitant with an increase in the transcriptional expression of /3-amyloid protein (Sekiguchi et al., 1994) . Studies are in progress in our laboratory to examine the functional role of RA-induced HSPG in CNS neuronal differentiation.
Clone 32.2 encodes the human cadherin-6 gene (Shimoyama et al., 1995) , which was recently isolated as another cadherin molecule that is expressed in human cancer cells besides epithelial (E-) and placental (P-) cadherins. Previous studies have demonstrated that various combinations of the three cadherins, E-, P-, and neural (N-) cadherins, were present in different stages of NT2/D1 cells. Similar levels of P-cadherin and E-cadherin were detected in untreated NT2/Dl cells and nonneuronal subpopulations of RA-differentiated NT2/D1 cells but not detected in the neuronal population of differentiated NT2/Dl cells. In contrast, a low level of N-cadherin was detected in undifferentiated NT2/Dl cells, whereas the highest level of Ncadherin was detected in NT2/Dl neurons (Ackerman et al., 1994) .
The dystroglycan gene (clone 15.31) was downregulated in NT2/D 1 cells during RA treatment. Two forms of dystroglycan (a and /3) encoded by the same dystroglycan gene are components of the dystrophinassociated membrane glycoprotein complex. This dystrophin-dystroglycan complex is important in myogenesis and is proposed to be a link between the extracellular matrix and the cytoskeleton. The expression of dystroglycan is ubiquitous throughout development, especially in cardiac, skeletal, and smooth muscle. Their presence in the ependymal cell lining of the developing neural tube and brain has also been reported (Schofield et al., 1995) . The expression of DEAD-box protein (clone 37.6) was demonstrated to be downregulated following RA treatment in the present study. One of the DEAD-box proteins, Vasa, has recently been found to be essential in the germ line development of Drosophila (Liang et al., 1994) . This finding raises the possibility that the high expression level of the DEAD-box protein in NT2/D1 cells might represent yet another embryonal carcinoma marker as in the case of SSEA-l (Andrews, 1984) . The decrease in the expression of DEAD-box protein concomitant with the differentiation of NT2/Dl cells might indicate the deviation of the cells from its embryonic phenotype. It is interesting that DEAD-box protein has recently been suggested to play an important role in the control of cell growth and division (Rafti et al., 1996) .
The differentially amplified bands can be classified in accordance with their responses to RA treatment or, alternatively, based on their roles involved in neuronal differentiation. Among the cloned differentially amplified RAP-PCR products that are identified in the present study, there are indeed examples that can potentially represent different stages of the process of neuronal differentiation. For example, there is the transcription factor SUPT4H, which is crucial for transcription and normal formation of chromatin, the RNA-binding proteins encoded by the DEAD-box genes, which are essential for translation and might also be involved in regulating the cell growth and division, cadherin, which may be involved in the axonal outgrowth and sorting process, and dystroglycan, which is implicated in neuronal connectivities. More importantly, we have identified a novel gene (clone 29.2) that is predominantly expressed in brain tissues (authors' unpublished data).
RAP-PCR can provide insight on the identity of candidate genes that are being regulated and on the selection of potential genes for further analysis. The isolation of several novel clones in the present study suggested that there are still several RA-responsive novel genes yet to be identified. By comparing isogenic cells subjected to different experimental treatment or with different developmental status, RAP-PCR reveals the difference in the pattern of gene expression. As demonstrated in the present study, RAP-PCR provides a tool for the identification of novel genes that are involved in different physiological processes (Welsh et al., 1992) . Furthermore, RAP-PCR can be used to investigate how the population of transcripts, i.e., regulation of mRNA expression, is being influenced without cloning a gene. Responding genes can be categorized and aligned to the respective treatment applied . Similarly, differential display has been used to investigate the genes differentially expressed in prenatal and neonatal mammalian brain (Dalal et al., 1994; Joseph et al., 1994) . Further studies are in progress in our laboratory to characterize the novel genes identified in the present study, to examine whether they are specific to the neuronal pathway, and to investigate how these novel genes are related to the RA-induced neuronal differentiation process.
